ATHENEX INC

Summary

Athenex operates as a biopharmaceutical company. The Company offers discovery, development, and commercialization of novel therapies for the treatment of cancer. Athenex serves patients globally.

Deals Overview

Total Deals2

Valued Deals1

Total Value£ 133 M

Avg. Deal Size£ 133 M

Market Context

Senior Management

Johnson Lau
Chairman and CEO
Dan Lang
President
Daniel Lang
Managing Director

Sort

05 May 2021|United States|Biotechnology

Target: KUUR

Bidder: ATHENEX INC

7 Service Providers

4 Target | 3 Bidder

25 Dealmakers

2 Target | 23 Bidder

£ 133 M

Value

02 Jul 2018|China|Pharmaceuticals

Target: AXIS THERAPEUTICS LIMITED

Bidder: ATHENEX INC

6 Service Providers

6 Bidder

6 Dealmakers

6 Bidder

n/a

Value

Explore deals beyond your search with a free MergerLinks account.

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy